A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma.

Trial Profile

A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories; TAP Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 May 2010 Additional trial identifier 1B-08-2 identified as reported by University of Southern California Norris Comprehensive Cancer Center record.
    • 13 May 2010 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center record no. 1B-08-2).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top